Global Clinical Next Generation Sequencing Industry

2024-2030 Global Clinical Next Generation Sequencing (NGS) Industry Research & Trends Analysis Report

Global Clinical Next Generation Sequencing Industry

2024-2030 Global Clinical Next Generation Sequencing (NGS) Industry Research & Trends Analysis Report


The Clinical Next Generation Sequencing (NGS) study provides a comprehensive overview of safety standards, market penetration, and innovation pipelines across major economies.

Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!

According to latest Research, the global market for Clinical Next Generation Sequencing (NGS) should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

China Clinical Next Generation Sequencing (NGS) market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

The United States Clinical Next Generation Sequencing (NGS) market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

In terms of type, Sequencing by Synthesis (SBS) segment holds a share about % in 2023 and will reach % in 2029; while in terms of application, Diagnostics has a share approximately % in 2023 and will grow at a CAGR % during 2023 and 2029.

The global key manufacturers of Clinical Next Generation Sequencing (NGS) include Agilent Technologies, Illumina, Thermo Fisher Scientific, Eurofins Scientific, BGI Group, Qiagen, Roche Diagnostics, Bio-Rad and Congenica, etc. In 2023, the global top five players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive study of the global market for Clinical Next Generation Sequencing (NGS). Report Highlights:

(1) Global Clinical Next Generation Sequencing (NGS) market size (value), history data from 2019-2024 and forecast data from 2024 to 2030.

(2) Global Clinical Next Generation Sequencing (NGS) market competitive situation, revenue and market share, from 2019 to 2024.

(3) China Clinical Next Generation Sequencing (NGS) market competitive situation, revenue and market share, from 2019 to 2024.

(4) Global Clinical Next Generation Sequencing (NGS) segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.

(5) Global Clinical Next Generation Sequencing (NGS) segment by type and by application and regional segment by type and by application.

(6) Clinical Next Generation Sequencing (NGS) industry supply chain, upstream, midstream and downstream analysis.

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Market segment by type, covers

Sequencing by Synthesis (SBS)

Nanopore Sequencing

Single-Molecule Real-Time (SMRT) Sequencing

Others

Market segment by application, can be divided into

Diagnostics

Drug Discovery & Designing

Medical Research

Others

Market segment by players, this report covers

Agilent Technologies

Illumina

Thermo Fisher Scientific

Eurofins Scientific

BGI Group

Qiagen

Roche Diagnostics

Bio-Rad

Congenica

Theragen Etex

PerkinElmer

Partek

Oxford Nanopore Technologies

Pacific Biosciences of California

Golden Helix

BioDatomics

PierianDx

DNAStar

1 Market Overview

1.1 Product Overview and Scope of Clinical Next Generation Sequencing (NGS)

1.2 Global Clinical Next Generation Sequencing (NGS) Market Size and Forecast

1.3 China Clinical Next Generation Sequencing (NGS) Market Size and Forecast

1.4 China Market Percentage in Global

1.4.1 By Revenue, China Clinical Next Generation Sequencing (NGS) Share in Global Market, 2019-2030

1.4.2 Clinical Next Generation Sequencing (NGS) Market Size: China VS Global, 2019-2030

1.5 Clinical Next Generation Sequencing (NGS) Market Dynamics

1.5.1 Clinical Next Generation Sequencing (NGS) Market Drivers

1.5.2 Clinical Next Generation Sequencing (NGS) Market Restraints

1.5.3 Clinical Next Generation Sequencing (NGS) Industry Trends

1.5.4 Clinical Next Generation Sequencing (NGS) Industry Policy

2 Global Competitive Situation by Company

2.1 Global Clinical Next Generation Sequencing (NGS) Revenue by Company (2019-2024)

2.2 Global Clinical Next Generation Sequencing (NGS) Participants, Market Position (Tier 1, Tier 2 and Tier 3)

2.3 Global Clinical Next Generation Sequencing (NGS) Concentration Ratio

2.4 Global Clinical Next Generation Sequencing (NGS) Mergers & Acquisitions, Expansion Plans

2.5 Global Clinical Next Generation Sequencing (NGS) Manufacturers Product Type

3 China Competitive Situation by Company

3.1 China Clinical Next Generation Sequencing (NGS) Revenue by Company (2019-2024)

3.2 China Clinical Next Generation Sequencing (NGS) Clinical Next Generation Sequencing (NGS) Participants, Market Position (Tier 1, Tier 2 and Tier 3)

3.3 China Clinical Next Generation Sequencing (NGS), Revenue Percentage of Local Players VS Foreign Manufacturers (2019-2024)

4 Industry Chain Analysis

4.1 Clinical Next Generation Sequencing (NGS) Industry Chain

4.2 Clinical Next Generation Sequencing (NGS) Upstream Analysis

4.3 Clinical Next Generation Sequencing (NGS) Midstream Analysis

4.4 Clinical Next Generation Sequencing (NGS) Downstream Analysis

5 Sights by Type

5.1 Clinical Next Generation Sequencing (NGS) Classification

5.1.1 Sequencing by Synthesis (SBS)

5.1.2 Nanopore Sequencing

5.1.3 Single-Molecule Real-Time (SMRT) Sequencing

5.1.4 Others

5.2 By Type, Global Clinical Next Generation Sequencing (NGS) Market Size & CAGR, 2019 VS 2024 VS 2030

5.3 By Type, Global Clinical Next Generation Sequencing (NGS) Revenue, 2019-2030

6 Sights by Application

6.1 Clinical Next Generation Sequencing (NGS) Segment by Application

6.1.1 Diagnostics

6.1.2 Drug Discovery & Designing

6.1.3 Medical Research

6.1.4 Others

6.2 By Application, Global Clinical Next Generation Sequencing (NGS) Market Size & CAGR, 2019 VS 2024 VS 2030

6.3 By Application, Global Clinical Next Generation Sequencing (NGS) Revenue, 2019-2030

7 Sales Sights by Region

7.1 By Region, Global Clinical Next Generation Sequencing (NGS) Market Size, 2019 VS 2024 VS 2030

7.2 By Region, Global Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

7.3 North America

7.3.1 North America Clinical Next Generation Sequencing (NGS) Market Size & Forecasts, 2019-2030

7.3.2 By Country, North America Clinical Next Generation Sequencing (NGS) Market Size Market Share

7.4 Europe

7.4.1 Europe Clinical Next Generation Sequencing (NGS) Market Size & Forecasts, 2019-2030

7.4.2 By Country, Europe Clinical Next Generation Sequencing (NGS) Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Clinical Next Generation Sequencing (NGS) Market Size & Forecasts, 2019-2030

7.5.2 By Country/Region, Asia Pacific Clinical Next Generation Sequencing (NGS) Market Size Market Share

7.6 South America

7.6.1 South America Clinical Next Generation Sequencing (NGS) Market Size & Forecasts, 2019-2030

7.6.2 By Country, South America Clinical Next Generation Sequencing (NGS) Market Size Market Share

7.7 Middle East & Africa

8 Sights by Country Level

8.1 By Country, Global Clinical Next Generation Sequencing (NGS) Market Size & CAGR，2019 VS 2024 VS 2030

8.2 By Country, Global Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.3 U.S.

8.3.1 U.S. Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.3.2 By Company, U.S. Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.3.3 By Type, U.S. Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.3.4 By Application, U.S. Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.4 Europe

8.4.1 Europe Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.4.2 By Company, Europe Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.4.3 By Type, Europe Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.4.4 By Application, Europe Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.5 China

8.5.1 China Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.5.2 By Company, China Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.5.3 By Type, China Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.5.4 By Application, China Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.6 Japan

8.6.1 Japan Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.6.2 By Company, Japan Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.6.3 By Type, Japan Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.6.4 By Application, Japan Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.7 South Korea

8.7.1 South Korea Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.7.2 By Company, South Korea Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.7.3 By Type, South Korea Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.7.4 By Application, South Korea Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.8 Southeast Asia

8.8.1 Southeast Asia Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.8.2 By Company, Southeast Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.8.3 By Type, Southeast Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.8.4 By Application, Southeast Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.9 India

8.9.1 India Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.9.2 By Company, India Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.9.3 By Type, India Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.9.4 By Application, India Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.10 Middle East & Asia

8.10.1 Middle East & Asia Clinical Next Generation Sequencing (NGS) Market Size, 2019-2030

8.10.2 By Company, Middle East & Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2019-2024

8.10.3 By Type, Middle East & Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

8.10.4 By Application, Middle East & Asia Clinical Next Generation Sequencing (NGS) Revenue Market Share, 2024 VS 2030

9 Global Manufacturers Profile

9.1 Agilent Technologies

9.1.1 Agilent Technologies Company Information, Head Office, Market Area and Industry Position

9.1.2 Agilent Technologies Company Profile and Main Business

9.1.3 Agilent Technologies Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.1.4 Agilent Technologies Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.1.5 Agilent Technologies Recent Developments

9.2 Illumina

9.2.1 Illumina Company Information, Head Office, Market Area and Industry Position

9.2.2 Illumina Company Profile and Main Business

9.2.3 Illumina Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.2.4 Illumina Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.2.5 Illumina Recent Developments

9.3 Thermo Fisher Scientific

9.3.1 Thermo Fisher Scientific Company Information, Head Office, Market Area and Industry Position

9.3.2 Thermo Fisher Scientific Company Profile and Main Business

9.3.3 Thermo Fisher Scientific Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.3.4 Thermo Fisher Scientific Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.3.5 Thermo Fisher Scientific Recent Developments

9.4 Eurofins Scientific

9.4.1 Eurofins Scientific Company Information, Head Office, Market Area and Industry Position

9.4.2 Eurofins Scientific Company Profile and Main Business

9.4.3 Eurofins Scientific Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.4.4 Eurofins Scientific Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.4.5 Eurofins Scientific Recent Developments

9.5 BGI Group

9.5.1 BGI Group Company Information, Head Office, Market Area and Industry Position

9.5.2 BGI Group Company Profile and Main Business

9.5.3 BGI Group Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.5.4 BGI Group Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.5.5 BGI Group Recent Developments

9.6 Qiagen

9.6.1 Qiagen Company Information, Head Office, Market Area and Industry Position

9.6.2 Qiagen Company Profile and Main Business

9.6.3 Qiagen Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.6.4 Qiagen Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.6.5 Qiagen Recent Developments

9.7 Roche Diagnostics

9.7.1 Roche Diagnostics Company Information, Head Office, Market Area and Industry Position

9.7.2 Roche Diagnostics Company Profile and Main Business

9.7.3 Roche Diagnostics Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.7.4 Roche Diagnostics Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.7.5 Roche Diagnostics Recent Developments

9.8 Bio-Rad

9.8.1 Bio-Rad Company Information, Head Office, Market Area and Industry Position

9.8.2 Bio-Rad Company Profile and Main Business

9.8.3 Bio-Rad Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.8.4 Bio-Rad Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.8.5 Bio-Rad Recent Developments

9.9 Congenica

9.9.1 Congenica Company Information, Head Office, Market Area and Industry Position

9.9.2 Congenica Company Profile and Main Business

9.9.3 Congenica Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.9.4 Congenica Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.9.5 Congenica Recent Developments

9.10 Theragen Etex

9.10.1 Theragen Etex Company Information, Head Office, Market Area and Industry Position

9.10.2 Theragen Etex Company Profile and Main Business

9.10.3 Theragen Etex Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.10.4 Theragen Etex Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.10.5 Theragen Etex Recent Developments

9.11 PerkinElmer

9.11.1 PerkinElmer Company Information, Head Office, Market Area and Industry Position

9.11.2 PerkinElmer Company Profile and Main Business

9.11.3 PerkinElmer Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.11.4 PerkinElmer Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.11.5 PerkinElmer Recent Developments

9.12 Partek

9.12.1 Partek Company Information, Head Office, Market Area and Industry Position

9.12.2 Partek Company Profile and Main Business

9.12.3 Partek Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.12.4 Partek Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.12.5 Partek Recent Developments

9.13 Oxford Nanopore Technologies

9.13.1 Oxford Nanopore Technologies Company Information, Head Office, Market Area and Industry Position

9.13.2 Oxford Nanopore Technologies Company Profile and Main Business

9.13.3 Oxford Nanopore Technologies Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.13.4 Oxford Nanopore Technologies Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.13.5 Oxford Nanopore Technologies Recent Developments

9.14 Pacific Biosciences of California

9.14.1 Pacific Biosciences of California Company Information, Head Office, Market Area and Industry Position

9.14.2 Pacific Biosciences of California Company Profile and Main Business

9.14.3 Pacific Biosciences of California Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.14.4 Pacific Biosciences of California Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.14.5 Pacific Biosciences of California Recent Developments

9.15 Golden Helix

9.15.1 Golden Helix Company Information, Head Office, Market Area and Industry Position

9.15.2 Golden Helix Company Profile and Main Business

9.15.3 Golden Helix Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.15.4 Golden Helix Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.15.5 Golden Helix Recent Developments

9.16 BioDatomics

9.16.1 BioDatomics Company Information, Head Office, Market Area and Industry Position

9.16.2 BioDatomics Company Profile and Main Business

9.16.3 BioDatomics Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.16.4 BioDatomics Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.16.5 BioDatomics Recent Developments

9.17 PierianDx

9.17.1 PierianDx Company Information, Head Office, Market Area and Industry Position

9.17.2 PierianDx Company Profile and Main Business

9.17.3 PierianDx Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.17.4 PierianDx Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.17.5 PierianDx Recent Developments

9.18 DNAStar

9.18.1 DNAStar Company Information, Head Office, Market Area and Industry Position

9.18.2 DNAStar Company Profile and Main Business

9.18.3 DNAStar Clinical Next Generation Sequencing (NGS) Models, Specifications and Application

9.18.4 DNAStar Clinical Next Generation Sequencing (NGS) Revenue and Gross Margin, 2019-2024

9.18.5 DNAStar Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Tables & Figures:
Show more
Research Methodology:
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Clinical Next Generation Sequencing (NGS) Market Size Estimation

To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.

Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.

Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.

We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.

Data Source

Secondary Sources

This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.

These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.

Market Size
  • Segmental value
  • Geographic Penetration
  • Product Adoption Rate for Different market
  • Journals, Websites, and Press Releases
  • Annual Reports and SEC Filings
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Market Intellix Data Repository
Market Position of Top Company
  • Product Financials
  • Geographic value Mix
  • Total Company value
  • Business/Segmental value Mix
Qualitative Analysis
  • Influence Factors
  • Market Potential
  • Market Risks and Opportunities
  • Industry Trends
  • Geographical Features
  • Government Policies
  • Company Websites and Press Releases
  • Public and Paid Databases
  • Annual Reports
  • Industry Associations
  • Market Intellix Data Repository

Primary Sources

As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.

On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.

These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.

Key Data Information from Primary Sources

Primary Sources Parameters Key Data
Market Segments(by Application, by Type)
  • Value by Type
  • Status and Forecast
  • Value by Application
  • Value by Regions, Status and Forecast (2025-2031)
  • Value Market Share by Type
  • Value Growth Rate by Type
  • Value by Application
  • Percentage and Growth Rate by Application
  • Value Growth Rate and Market Share by Regions
  • Market Size Status and Forecast (2025-2031)
Total Market
  • Overall Size, Status and Forecast
  • Market Size Status and Forecast (2025-2031)
Frequently asked questions(FAQ's):
Why is the Clinical Next Generation Sequencing (NGS) Market trending toward high growth trajectories?
A dynamic process in the Clinical Next Generation Sequencing (NGS) Market is initiated by new entrants, including competitors from unrelated industries, in addition to the established players like Illumina, PacBio, Oxford Nanopore, Thermo Fisher, Agilent.
What is the Clinical Next Generation Sequencing (NGS) Market really preparing for?
Companies in the Clinical Next Generation Sequencing (NGS) Industry will need to adapt swiftly to the behavioral changes that are reshaping consumer decision journeys.
What are the major applications of the Clinical Next Generation Sequencing (NGS) Market?
Depending upon the type of applications, the Clinical Next Generation Sequencing (NGS) Market has been segmented into and other applications.
What is the estimated size & growth rate of the Clinical Next Generation Sequencing (NGS) Market?
In recent years, the Clinical Next Generation Sequencing (NGS) Market has grown at an incredible rate. From 2025 to 2030, the market is expected to grow at a CAGR of yy%.
What is Clinical Next Generation Sequencing (NGS) Market Concentration Rate?
In addition to the Clinical Next Generation Sequencing (NGS) Market share analysis by competitors, the report also includes chapters on the HHI Index, CR4, and CR8 to characterize the concentration rate and competitive character of the Clinical Next Generation Sequencing (NGS) Market.
What is the CAGR at which the Clinical Next Generation Sequencing (NGS) Market can expand?
During the forecast years, the Clinical Next Generation Sequencing (NGS) Market can thrive with a robust CAGR.